Glycomics of Prostate Cancer: Updates

Overview

Journal Expert Rev Proteomics

Publisher Informa Healthcare

Date 2018 Nov 20

PMID 30451032

Citations 15

Authors

Jan Tkac

Tomas Bertok

Michal Hires

Eduard Jane

Lenka Lorencova

Peter Kasak

Affiliations

Soon will be listed here.

Abstract

: Prostate cancer (PCa) is a life-threatening disease affecting millions of men. The current best PCa biomarker (level of prostate-specific antigen in serum) lacks specificity for PCa diagnostics and this is why novel PCa biomarkers in addition to the conventional ones based on biomolecules such as DNA, RNA and proteins need to be identified. : This review details the potential of glycans-based biomarkers to become diagnostic, prognostic, predictive and therapeutic PCa biomarkers with a brief description of the innovative approaches applied to glycan analysis to date. Finally, the review covers the possibility to use exosomes as a rich source of glycans for future innovative and advanced diagnostics of PCa. The review covers updates in the field since 2016. : The summary provided in this review paper suggests that glycan-based biomarkers can offer high-assay accuracy not only for diagnostic purposes but also for monitoring/surveillance of the PCa disease.

Citing Articles

N-Acetylated Monosaccharides and Derived Glycan Structures Occurring in N- and O-Glycans During Prostate Cancer Development.

Bertok T, Jane E, Hires M, Tkac J Cancers (Basel). 2024; 16(22).

PMID: 39594740 PMC: 11592093. DOI: 10.3390/cancers16223786.

Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen.

Halldorsson S, Hillringhaus L, Hojer C, Muranyi A, Schraeml M, Lange M Sci Rep. 2024; 14(1):16512.

PMID: 39020051 PMC: 11254934. DOI: 10.1038/s41598-024-67545-1.

Medical Relevance, State-of-the-Art and Perspectives of "Sweet Metacode" in Liquid Biopsy Approaches.

Pinkeova A, Kosutova N, Jane E, Lorencova L, Bertokova A, Bertok T Diagnostics (Basel). 2024; 14(7).

PMID: 38611626 PMC: 11011756. DOI: 10.3390/diagnostics14070713.

Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.

Pinkeova A, Tomikova A, Bertokova A, Fabinyova E, Bartova R, Jane E PLoS One. 2024; 19(3):e0300430.

PMID: 38498504 PMC: 10947713. DOI: 10.1371/journal.pone.0300430.

Amperometric Miniaturised Portable Enzymatic Nanobiosensor for the Ultrasensitive Analysis of a Prostate Cancer Biomarker.

Hroncekova S, Lorencova L, Bertok T, Hires M, Jane E, Bucko M J Funct Biomater. 2023; 14(3).

PMID: 36976085 PMC: 10056543. DOI: 10.3390/jfb14030161.

References

Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K . Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer. Int J Mol Sci. 2017; 18(2). PMC: 5343797. DOI: 10.3390/ijms18020261. View

Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y . Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. Biochem Biophys Res Commun. 2016; 470(1):150-156. DOI: 10.1016/j.bbrc.2016.01.011. View

Yang S, Hu Y, Sokoll L, Zhang H . Simultaneous quantification of N- and O-glycans using a solid-phase method. Nat Protoc. 2017; 12(6):1229-1244. PMC: 5877797. DOI: 10.1038/nprot.2017.034. View

Pinho S, Reis C . Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015; 15(9):540-55. DOI: 10.1038/nrc3982. View

Jia X, Chen J, Sun S, Yang W, Yang S, Shah P . Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics. 2016; 16(23):2989-2996. PMC: 5407186. DOI: 10.1002/pmic.201500506. View

Jolly P, Damborsky P, Madaboosi N, Soares R, Chu V, Conde J . DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers. Biosens Bioelectron. 2016; 79:313-9. DOI: 10.1016/j.bios.2015.12.058. View

Gerlach J, Griffin M . Getting to know the extracellular vesicle glycome. Mol Biosyst. 2016; 12(4):1071-81. DOI: 10.1039/c5mb00835b. View

Kammeijer G, Nouta J, de la Rosette J, de Reijke T, Wuhrer M . An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen. Anal Chem. 2018; 90(7):4414-4421. PMC: 5885261. DOI: 10.1021/acs.analchem.7b04281. View

Jia G, Dong Z, Sun C, Wen F, Wang H, Guo H . Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia. Oncotarget. 2017; 8(44):76987-76999. PMC: 5652757. DOI: 10.18632/oncotarget.20299. View

10.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

11.

Bhanushali P, Badgujar S, Tripathi M, Gupta S, Murthy V, Krishnasastry M . Development of glycan specific lectin based immunoassay for detection of prostate specific antigen. Int J Biol Macromol. 2016; 86:468-80. DOI: 10.1016/j.ijbiomac.2016.01.110. View

12.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

13.

Chen X, Nagai Y, Zhu Z, Ruan H, Peehl D, Greene M . A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77. Oncotarget. 2018; 9(3):3631-3640. PMC: 5790488. DOI: 10.18632/oncotarget.23341. View

14.

Munkley J, Mills I, Elliott D . The role of glycans in the development and progression of prostate cancer. Nat Rev Urol. 2016; 13(6):324-33. DOI: 10.1038/nrurol.2016.65. View

15.

Royo F, Diwan I, Tackett M, Zuniga P, Sanchez-Mosquera P, Loizaga-Iriarte A . Comparative miRNA Analysis of Urine Extracellular Vesicles Isolated through Five Different Methods. Cancers (Basel). 2016; 8(12). PMC: 5187510. DOI: 10.3390/cancers8120112. View

16.

Reynolds N, Mohammadalipour A, Hall C, Asghari Adib A, Farnoud A, Burdick M . Galectin-1 Influences Breast Cancer Cell Adhesion to E-selectin Ligand Intermediaries. Cell Mol Bioeng. 2019; 11(1):37-52. PMC: 6816655. DOI: 10.1007/s12195-017-0512-9. View

17.

Pihikova D, Pakanova Z, Nemcovic M, Barath P, Belicky S, Bertok T . Sweet characterisation of prostate specific antigen using electrochemical lectin-based immunosensor assay and MALDI TOF/TOF analysis: Focus on sialic acid. Proteomics. 2016; 16(24):3085-3095. PMC: 5659381. DOI: 10.1002/pmic.201500463. View

18.

Munkley J, Elliott D . Hallmarks of glycosylation in cancer. Oncotarget. 2016; 7(23):35478-89. PMC: 5085245. DOI: 10.18632/oncotarget.8155. View

19.

Wang W, Luo J, Wang S . Recent Progress in Isolation and Detection of Extracellular Vesicles for Cancer Diagnostics. Adv Healthc Mater. 2018; 7(20):e1800484. DOI: 10.1002/adhm.201800484. View

20.

Pihikova D, Kasak P, Kubanikova P, Sokol R, Tkac J . Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples. Anal Chim Acta. 2016; 934:72-9. PMC: 5659379. DOI: 10.1016/j.aca.2016.06.043. View